Navigation Links
Inovio Pharmaceuticals to Present at JMP Investor Conference
Date:7/9/2012

BLUE BELL, Pa., July 9, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) announced today that Dr. J. Joseph Kim, President and CEO, will present an overview of the company at the JMP Securities Healthcare Conference.

7th Annual JMP Securities Healthcare Conference July 12-13, 2012 700 5th Avenue at 55th Street, The Peninsula New York, NY

Inovio Presentation Friday, July 13 1:30 – 2:00 p.m. EDT J. Joseph Kim, PhD, President and CEO

A live and archived webcast of the presentation will be accessible on Inovio's website at http://www.inovio.com/

About Inovio Pharmaceuticals, Inc.

Inovio is revolutionizing vaccines to prevent and treat today's cancers and challenging infectious diseases. Its SynCon® vaccines are designed to provide universal cross-strain protection against known as well as newly emergent unmatched strains of pathogens such as influenza. These synthetic vaccines, in combination with Inovio's proprietary electroporation delivery, have been shown in humans to generate best-in-class immune responses with a favorable safety profile. Inovio's clinical programs include Phase II studies for cervical dysplasia, leukemia and hepatitis C virus and Phase I studies for influenza and HIV. Partners and collaborators include the University of Pennsylvania, Merck, ChronTech, National Cancer Institute, U.S. Military HIV Research Program, NIH, HIV Vaccines Trial Network, University of Southampton, US Dept. of Homeland Security and PATH Malaria Vaccine Initiative. More information is available at www.inovio.com.

This press release contains certain forward-looking statements relating to our business, including our plans to develop electroporation-based drug and gene delivery technologies and DNA vaccines and our capital resources. Actual events or results may differ from the expectations set forth herein as a result of a number of factors, including uncertainties inherent in pre-clinical studies, clinical trials and product development programs (including, but not limited to, the fact that pre-clinical and clinical results referenced in this release may not be indicative of results achievable in other trials or for other indications, that the studies or trials may not be successful or achieve the results desired, that pre-clinical studies and clinical trials may not commence or be completed in the time periods anticipated, that results from one study may not necessarily be reflected or supported by the results of other similar studies and that results from an animal study may not be indicative of results achievable in human studies), the availability of funding to support continuing research and studies in an effort to prove safety and efficacy of electroporation technology as a delivery mechanism or develop viable DNA vaccines, the adequacy of our capital resources, the availability or potential availability of alternative therapies or treatments for the conditions targeted by the company or its collaborators, including alternatives that may be more efficacious or cost-effective than any therapy or treatment that the company and its collaborators hope to develop, evaluation of potential opportunities, issues involving product liability, issues involving patents and whether they or licenses to them will provide the company with meaningful protection from others using the covered technologies, whether such proprietary rights are enforceable or defensible or infringe or allegedly infringe on rights of others or can withstand claims of invalidity and whether the company can finance or devote other significant resources that may be necessary to prosecute, protect or defend them, the level of corporate expenditures, assessments of the company's technology by potential corporate or other partners or collaborators, capital market conditions, the impact of government healthcare proposals and other factors set forth in our Annual Report on Form 10-K for the year ended December 31, 2011, our Form 10-Q for the quarter ended March 31, 2012, and other regulatory filings from time to time. There can be no assurance that any product in Inovio's pipeline will be successfully developed or manufactured, that final results of clinical studies will be supportive of regulatory approvals required to market licensed products, or that any of the forward-looking information provided herein will be proven accurate.

CONTACTS:

Investors: Bernie Hertel, Inovio Pharmaceuticals 858-410-3101 bhertel@inovio.comMedia: Jeff Richardson, Inovio Pharmaceuticals 267-440-4211 jrichardson@inovio.com

(Logo:  http://photos.prnewswire.com/prnh/20120131/LA44118LOGO)


'/>"/>
SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Inovio Pharmaceuticals Universal Avian Flu Vaccine Generates Protective Antibody Responses Against Six H5N1 Viruses in Phase I Trial
2. Inovio Pharmaceuticals to Present at SPI 2012
3. Inovio Pharmaceuticals Reports 2012 First Quarter Financial Results
4. Inovio Pharmaceuticals Granted U.S. Patent Protection for Synthetic Vaccine for Cervical Dysplasia and Cancer
5. Inspiration Biopharmaceuticals Reports Positive Interim Results from the Accur8 Phase 2/3 Study of OBI-1 in Acquired Hemophilia A at WFH 2012 World Congress
6. Vanda Pharmaceuticals to Present at the JMP Securities Healthcare Conference
7. Amgen Completes Acquisition of KAI Pharmaceuticals
8. Optimer Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
9. Arena Pharmaceuticals Promotes Craig M. Audet to Executive Officer as Senior Vice President, Operations and Head of Global Regulatory Affairs
10. Isis Pharmaceuticals to Present at the 7th Annual JMP Securities Healthcare Conference
11. Law Office of Brodsky & Smith, LLC Announces Investigation of Amylin Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... Israel , May 27, 2016 ... an innovative biopharmaceutical company focused on late-stage drug ... Dexcel Pharma of pivotal batches required ... and Drug Administration (FDA). This follows Kitov,s ... Phase III trial successfully met its primary efficacy ...
(Date:5/26/2016)... A key trend that will ... of new treatments. Cardax, a development stage life sciences ... therapy is expected to fulfil large unmet medical needs ... studies to develop new treatments for osteoarthritis. One such ... in osteoarthritis are being investigated, and early trials of ...
(Date:5/25/2016)... 25,2016 FDA 510(k) clearance ... platform for urological and surgical applications ... of Cellvizio®, the multidisciplinary confocal laser endomicroscopy (CLE) ... the US with the 12 th 510(k) ... (FDA). This new FDA clearance covers Confocal Miniprobes ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... On Memorial Day, Hope For ... their lives in military battle for the country. The nonprofit Hope For Heroes ... more programs that empower independence for disabled military veterans, as well as police, firemen, ...
(Date:5/26/2016)... , ... May 26, 2016 , ... MadgeTech will be ... engineered, and manufactured in Warner, New Hampshire at the MadgeTech headquarters. With products sold ... monitoring solutions trusted by government agencies, including NASA. , In 2012, NASA strategically ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... In an effort to provide hair restoration ... to both Snapchat users and those who do not use the app. Dr. Mohebi, the ... new page, Dr. Mohebi Live . , Dr. Mohebi says, “The positive response ...
(Date:5/26/2016)... Tampa, Fla. (PRWEB) , ... May 26, 2016 , ... ... Center (AHEC) to host a six-week smoking cessation class starting June 6 at their ... AHEC’s website, http://www.gnahec.org . , Additionally, the Lung Institute has created a free ...
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... The MIAMI ... events featuring guest speaker Dr. Adonis Maiquez MD, ABAARM. Dr. Adonis , Wellness ... Regenerative Medicine, and a member of the Institute for Functional Medicine. , He also ...
Breaking Medicine News(10 mins):